乳腺癌原发灶和腋窝转移淋巴结中雌激素受体、孕激素受体、人表皮生长因子受体2及Ki-67表达情况的比较

Comparison of the expression of estrogen receptor,progesterone receptor,human epidermal growth factor receptor 2 and Ki-67 in primary breast cancer and axillary metastatic lymph nodes

目的比较乳腺癌原发灶和腋窝转移淋巴结中雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)和Ki-67表达情况。方法收集50例乳腺癌患者的乳腺癌原发灶组织和腋窝转移淋巴结组织,采用免疫组化染色法检测ER、PR、HER2和Ki-67表达情况。比较乳腺癌原发灶和腋窝转移淋巴结中ER、PR、HER2和Ki-67表达情况。结果乳腺癌原发灶和腋窝转移淋巴结中ER、PR、HER2阳性率比较,差异均无统计学意义(P﹥0.05)。乳腺癌原发灶中Ki-67高表达率为70%,高于腋窝转移淋巴结的60%,差异有统计学意义(P﹤0.05)。在乳腺癌原发灶和腋窝转移淋巴结中,ER、PR、HER2和Ki-67表达不一致率分别为8%(4/50)、12%(6/50)、6%(3/50)和30%(15/50)。结论乳腺癌原发灶与腋窝转移淋巴结中ER、PR和HER2表达均具有高度一致性,术后病理标本检测原发灶中ER、PR和HER2的表达可为乳腺癌的治疗和预后评估提供依据,但乳腺癌原发灶和腋窝转移淋巴结中Ki-67需同时检测。

Objective To compare the expression of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor 2(HER2)and Ki-67 in primary breast cancer and axillary metastatic lymph nodes.Method The tissues of primary breast cancer and axillary metastatic lymph nodes in 50 patients with breast cancer were collected.The expression of ER,PR,HER2 and Ki-67 were detected by immunohistochemistry staining and compared in primary breast cancer and axillary metastatic lymph nodes.Result There were no significant differences for the positive rate of ER,PR and HER2 in primary breast cancer and axillary metastatic lymph nodes(P>0.05).The high expression rate of Ki-67 in primary breast cancer was 70%,higher than 60%in axillary metastatic lymph nodes,and the difference was statistically significant(P<0.05).In primary breast cancer and axillary metastatic lymph nodes,the discordance rates for expression of ER,PR,HER2 and Ki-67 were 8%(4/50),12%(6/50),6%(3/50)and 30%(15/50),respectively.Conclusion There are higher concordances for the expression of ER,PR and HER2 in primary breast cancer and axillary metastatic lymph nodes.Postoperative pathological samples show that the expression of ER,PR and HER2 in the primary lesion can provide a basis for the treatment and prognosis evaluation of breast cancer,but Ki-67 in the primary breast cancer and axillary metastatic lymph nodes should be detected simultaneously.